TY - JOUR
T1 - Very long-chain acyl-CoA dehydrogenase deficiency and type I diabetes mellitus
T2 - Case report and management challenges
AU - Al-Busaidi, Salim Ahmed
AU - Al Nou'mani, Jawaher Al
AU - Al-Falahi, Zubaida
AU - Al-Farsi, Rajaa
AU - Kumar, Suneel
AU - Al-Murshedi, Fathiya
AU - Awlad-Thani, Kathiya
AU - Al Nabhani, Ayda
AU - Al Alawi, Abdullah M.
N1 - Publisher Copyright:
© 2023 The Canadian Society of Clinical Chemists
PY - 2023/6
Y1 - 2023/6
N2 - Background: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) is a rare autosomal recessive disorder of fatty acid metabolism. Its clinical presentation includes hypoketotic hypoglycemia and potentially life-threatening multiorgan dysfunction.Therefore, the cornerstone of management includes avoiding fasting, dietary modification, and monitoring for complications. The co-occurrence of type 1 diabetes mellitus (DM1) with VLCADD has not been described in the literature. Case report: A 14-year-old male with a known diagnosis of VLCADD presented with vomiting, epigastric pain, hyperglycemia, and high anion gap metabolic acidosis. He was diagnosed with DM1 and managed with insulin therapy while maintaining his high complex carbohydrate, low long-chain fatty acids diet with medium-chain triglyceride supplementation. The primary diagnosis (VLCADD) makes the management of DM1 in this patient challenging as hyperglycemia related to the lack of insulin puts the patient at risk of intracellular glucose depletion and hence increases the risk for major metabolic decompensation.Conversely, adjustment of the dose of insulin requires more attention to avoid hypoglycemia. Both situations represent increased risks compared to managing DM1 alone and need a patient-centred approach, with close follow-up by a multidisciplinary team. Conclusion: We present a novel case of DM1 in a patient with VLCADD. The case describes a general management approach and highlights the challenging aspects of managing a patient with two diseases with different potentially paradoxical life-threatening complications.
AB - Background: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) is a rare autosomal recessive disorder of fatty acid metabolism. Its clinical presentation includes hypoketotic hypoglycemia and potentially life-threatening multiorgan dysfunction.Therefore, the cornerstone of management includes avoiding fasting, dietary modification, and monitoring for complications. The co-occurrence of type 1 diabetes mellitus (DM1) with VLCADD has not been described in the literature. Case report: A 14-year-old male with a known diagnosis of VLCADD presented with vomiting, epigastric pain, hyperglycemia, and high anion gap metabolic acidosis. He was diagnosed with DM1 and managed with insulin therapy while maintaining his high complex carbohydrate, low long-chain fatty acids diet with medium-chain triglyceride supplementation. The primary diagnosis (VLCADD) makes the management of DM1 in this patient challenging as hyperglycemia related to the lack of insulin puts the patient at risk of intracellular glucose depletion and hence increases the risk for major metabolic decompensation.Conversely, adjustment of the dose of insulin requires more attention to avoid hypoglycemia. Both situations represent increased risks compared to managing DM1 alone and need a patient-centred approach, with close follow-up by a multidisciplinary team. Conclusion: We present a novel case of DM1 in a patient with VLCADD. The case describes a general management approach and highlights the challenging aspects of managing a patient with two diseases with different potentially paradoxical life-threatening complications.
KW - Diabetes mellitus
KW - Fatty acid oxidation disorders
KW - Very long-chain acyl-CoA dehydrogenase deficiency
KW - VLCAD
UR - http://www.scopus.com/inward/record.url?scp=85149759026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149759026&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2023.03.005
DO - 10.1016/j.clinbiochem.2023.03.005
M3 - Article
C2 - 36893960
AN - SCOPUS:85149759026
SN - 0009-9120
VL - 116
SP - 16
EP - 19
JO - Clinical Biochemistry
JF - Clinical Biochemistry
ER -